RxDoctor Payments Data

Steven Hess, DO

Family Medicine · Spartanburg, SCNPI 1063490910

Payments from drug & device makers

$11,220in general payments, 2019–2025

Across 590 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$1K
  • Pfizer$622
  • GSK$528
  • Novo Nordisk$489
  • Lilly USA, LLC$440
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$11,07499%
  • Education$1461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)71$2,736
AbbVie(2 entities)74$1,130
Pfizer39$622
GSK40$528
Novo Nordisk35$489
Lilly USA, LLC31$440
Abbott15$308
Amgen20$306
Mannkind Corporation17$288
Boehringer Ingelheim18$259
Daiichi Sankyo Inc.13$254
Amarin Pharma, Inc.16$233
Takeda Pharmaceuticals U.S.A., Inc.13$211
Sanofi-aventis U.S. LLC12$209
Astellas Pharma US Inc7$205
Esperion Therapeutics, Inc.10$189
Bayer11$187
Dexcom, Inc.9$155
Kowa Pharmaceuticals America, Inc.11$145
Novartis8$136
Antares Pharma, Inc.9$135
Biohaven Pharmaceuticals, Inc.6$130
Merck8$124
Seqirus USA Inc6$119
Eisai Inc.6$114
Medtronic3$107
Exact Sciences7$102
Mylan Specialty L.p.4$80
Abiomed3$71
Biohaven Pharmaceutical Holding Company Ltd.4$70
Genentech USA, Inc.4$62
Xeris Pharmaceuticals, Inc.3$56
Insulet Corporation2$54
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$51
Johnson & Johnson3$51
Sumitomo Pharma America, Inc.2$50
Shield Therapeutics Inc3$48
VBI Vaccine (delaware) Inc.2$44
Clarus Therapeutics Inc.3$44
Halozyme Inc2$40
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$39
Phathom Pharmaceuticals, Inc.2$36
Verona Pharma, Inc.2$34
Teva Pharmaceuticals USA, Inc.2$34
Inari Medical, Inc.2$34
Idorsia Pharmaceuticals US Inc2$31
Corcept Therapeutics2$30
Zealand Pharma US, Inc.1$29
Arbor Pharmaceuticals, Inc.1$29
Currax Pharmaceuticals LLC2$28
Ironwood Pharmaceuticals, Inc2$24
Stryker1$22
Supernus Pharmaceuticals, Inc.1$22
Nabriva Therapeutics, PLC1$19
Axsome Therapeutics, Inc.1$19
Tonix Medicines, Inc.1$18
Edwards Lifesciences1$18
E.r. Squibb & Sons, L.L.C.1$16
Philips North America LLC1$16
Vivus LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,220 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$311,959
Medicare patients
480
Services billed
8,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$142,094
EliquisApixaban159$141,329
FarxigaDapagliflozin Propanediol86$73,123
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$48,995
XareltoRivaroxaban63$47,972
MounjaroTirzepatide28$47,879
JardianceEmpagliflozin47$45,183
Tresiba Flextouch U-200Insulin Degludec52$38,937
JanuviaSitagliptin Phosphate48$38,567
LinzessLinaclotide20$21,860
Janumet XrSitagliptin Phos/Metformin Hcl28$18,197
RybelsusSemaglutide13$14,091
MyrbetriqMirabegron22$13,351
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$9,789
Tresiba Flextouch U-100Insulin Degludec19$9,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$489$156,185124 claims
PfizerEliquis$622$141,329159 claims
AstraZenecaFarxiga$2,736$73,12386 claims
MerckJanuvia, Janumet Xr$124$56,76476 claims
GSKTrelegy Ellipta$528$48,99569 claims
Johnson & JohnsonXarelto$51$47,97263 claims
Lilly USA, LLCMounjaro$440$47,87928 claims
Boehringer IngelheimJardiance$259$45,18347 claims
AbbVieLinzess, Namzaric, Synthroid$1,130$33,213115 claims
Astellas Pharma US IncMyrbetriq$205$13,35122 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$211$7,32015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →